Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
Join our Virtual Triathlon Challenge and swim, cycle and run while raising money to fund Breakthrough T1D’s life-changing type 1 research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > About Breakthrough T1D UK & our impact > Our research > Research projects > Calculating a type 1 diabetes risk score
Richard is designing a computer model that can calculate a person’s type 1 diabetes risk score by combining factors including their genes, family history of diabetes, and the number of islet autoantibodies they have. Islet auto antibodies are biological markers in the blood that show the immune attack that happens in type 1 has begun.
The risk score can be used to predict how likely an individual is to develop type 1 at different time points. As well as helping families plan for the future, this prediction tool could be a more cost-efficient and effective population screening method for type 1 diabetes.
Richard and his team will develop the tool us ing data from other studies including two screening projects TrialNet and the TEDDY study. The TEDDY study, which was co-funded by Breakthrough T1D UK, also investigated causes of type 1 in young children. The study will help Richard understand the factors that could influence whether a child is likely to develop type 1. The researchers will then use these additional factors to improve their prediction model.
The researchers have developed a new approach to predicting which babies will develop type 1 diabetes. He has created a prototype of the risk calculator, which he is now testing. It uses data from people of a variety of ethnicities to make sure the tool can be used by anyone.
Richard plans to make the model more accessible by developing a simple online calculator and app. This is something that the diabetes team at the University of Exeter has already successfully achieved with the Exeter MODY calculator.
Richard will share his risk model and the technology behind it with other researchers and clinicians. This will help researchers trying to understand the causes of type 1, slow or prevent type 1, improve screening methods, and those running clinical trials of treatments for type 1.
Emerging drugs that target the immune system (immune therapies) and protect insulin-producing cells are most effective early in type 1 development. Screening is the only way to find people in the preclinical stage of type 1, which is before symptoms develop. Teplizumab is a drug available for people with preclinical type 1 in the US. We need an established screening programme in the UK before so that we know who will benefit from teplizumab and other drugs when they are licensed in the UK.
Most people who are diagnosed with type 1 don’t have any family members who also have it. People who aren’t affected by type 1 may be unfamiliar with the signs and symptoms of type 1. Screening the population allows time for people at risk to become aware of the signs to look out for and learn about managing type 1. This helps prevent people being diagnosed as an emergency in diabetic ketoacidosis (DKA) .
We are also co-funding the ELSA study, which is screening 20,000 children across the UK to find those at high risk of developing type 1. Both studies are part of our research to determine the most practical and effective ways of screening the UK population for type 1.
Dr Matthew Anson is studying whether hybrid closed loop technology, also known as an artificial pancreas, affects the worsening of diabetic eye disease.
Dr Samet Sahin is developing a simple tool to allow healthcare professionals to quickly and easily check someone’s C-peptide levels, a measure of how much insulin they are releasing.
Dr Thomas George Hill is studying a type of pancreatic islet cell, called a delta cell, which he thinks could be targeted with a treatment to help prevent low blood glucose in type 1 diabetes.
Dr Rebecca Dewhurst-Trigg is investigating how supportive cells called mesenchymal stromal cells may help protect insulin-making beta cells from being destroyed in type 1 diabetes.
